Document:

<PAGE>

                                                                    Exhibit 10.2
                                                                    ------------

                          AMENDMENT TO LIMITED WAIVER
                          ---------------------------

          This Amendment to Limited Waiver (the "Amendment") is entered into as
of September 27, 2001 by and among:

     Cybex International, Inc., a New York corporation, having a place of
     business at 10 Trotter Drive, Medway, Massachusetts 02053 (the "Borrower");

     Cybex Financial Corp., Eagle Performance Systems, Inc., General Medical
     Equipment, Ltd., Lumex Bed Systems, Inc., Cybex Fitness Gerate Vertriebs
     GmBH, and Tectrix Fitness Equipment, Inc.  (individually, a "Guarantor" and
     collectively, the "Guarantors");

     The Lenders party to the Credit Agreement (defined below) (hereinafter
     collectively, the "Lenders"); and

     First Union National Bank, as Administrative Agent for the Lenders
     (hereinafter, in such capacity, the "Administrative Agent"), having a
     principal place of business at One First Union Center, 301 South College
     Street, TW-5, Charlotte, North Carolina 28288-0537;

in consideration of the mutual covenants herein contained and benefits to be
derived herefrom.

                                  WITNESSETH:
                                  ----------

1.   Background.  On July 25, 2001, the Administrative Agent, the Lenders, the
     ----------
Borrower and the Guarantors entered into a certain Limited Waiver agreement (the
"Limited Waiver") with respect to certain terms and conditions of that certain
Credit Agreement, (as defined in the Limited Waiver) by and among others, the
Administrative Agent, the Lenders, the Borrower and the Guarantors.  The
Borrowers and the Guarantors have asked that the Lenders and the Administrative
Agent amend certain provisions of the Limited Waiver, and the Lenders and the
Administrative Agent are willing to amend the Limited Waiver, on the terms and
conditions set forth herein.

2.   Definitions.   All capitalized terms used herein and not otherwise defined
     -----------
shall have the same meaning herein as in the Limited Waiver and the Credit
Agreement, as applicable.

3.   Waiver of Claims
     ----------------

     a.   The Borrower and the Guarantors each acknowledge and agree that they
          do not have any offsets, defenses, or counterclaims against the
          Administrative Agent, the Issuing Lender, or the Lenders with respect
          to the Credit Agreement, the Guaranties, the Limited Waiver any other
          Credit Documents, or otherwise. To the extent that any such offsets,
          defenses or counterclaims may exist, the Borrower
<PAGE>

          and each Guarantor hereby WAIVES and RELEASES the Administrative
                                    ------     --------
          Agent, the Issuing Lender, the Lenders and their respective officers,
          representatives, counsel, trustees, and directors from any and all
          actions, causes of action, claims, demands, damages, and liabilities
          of whatever kind or nature, in law or in equity, now known or unknown,
          suspected or unsuspected. The Borrower and each Guarantor shall
          execute and deliver to the Administrative Agent, the Issuing Lender
          and each Lender such releases as the Administrative Agent, the Issuing
          Lender or any Lender may request to confirm the foregoing.

     b.   The Borrower and each Guarantor hereby ratifies and confirms that the
          Obligations (as modified hereby) are, and will continue to be, secured
          by the Collateral and the Guarantor Collateral.

4.   Amendment to Limited Waiver.  The Limited Waiver is hereby amended as
     ---------------------------
follows:

     a.   The term "Payment Event", as defined in the Limited Waiver, shall also
          include the failure of the Borrower make certain principal payments
          which were or will be due on August 31 or September 30, 2001.

     b.   Paragraph 4(a) of the Limited Waiver is hereby amended by inserting
          the words "and August and September" after the word "July" in the 3rd
          line thereof.

     c.   Paragraph 4(a)(ii) of the Limited Waiver is hereby deleted in its
          entirety, and the following substituted in its stead:

          ii.  Any regularly scheduled payments of  principal on the Term Loan
               due and payable through September 30, 2001, to the extent not
               previously paid, shall be paid on October 12, 2001.

     d.   Paragraph 4(c) of the Limited Waiver is hereby amended by deleting the
          reference to "August 16, 2001" in subclause (i) thereof and
          substituting "October 12, 2001" in its stead.

     e.   Paragraph 5 of the Limited Waiver is hereby deleted in its entirety,
          and the Administrative Agent and the Lenders hereby waive any default
          caused by the failure of the Borrower to consummate the sale-leaseback
          transaction therein described.

5.   Conditions to Effectiveness. This Amendment shall not be effective until
     ---------------------------
     each of the following conditions precedent have been fulfilled to the
     satisfaction of the Administrative Agent and the Lenders:

     a.   This Amendment shall have been duly executed and delivered by the
          respective parties hereto and shall be in form and substance
          satisfactory to the Administrative Agent and each of the Lenders.

                                       2
<PAGE>

     b.   All action on the part of the Borrower and each Guarantor necessary
          for the valid execution, delivery and performance by the Borrower and
          each Guarantor of this Amendment shall have been duly and effectively
          taken and evidence thereof satisfactory to the Administrative Agent
          and the Lenders shall have been provided to the Administrative Agent
          and each of the Lenders.

     c.   The Borrower shall have paid to the Administrative Agent and Lenders
          all expenses (including reasonable attorneys fees) and other amounts
          then due and owing pursuant to the Credit Documents for which invoices
          have been presented as of the date of execution hereof.

     d.   The Borrower and the Guarantors shall have provided such additional
          instruments and documents to the Administrative Agent and the Lenders
          as the Administrative Agent and the Administrative Agent's counsel may
          have reasonably requested.

6.   General.
     -------

     a.   This Amendment shall be binding upon the Borrower and the Guarantors
          and their respective successors and assigns and shall enure to the
          benefit of the Administrative Agent, the Lenders, and their respective
          successors and assigns.

     b.   Any determination that any provision of this Amendment or any
          application thereof is invalid, illegal, or unenforceable in any
          respect in any instance shall not affect the validity, legality, or
          enforceability of such provision in any other instance, or the
          validity, legality, or enforceability of any other provision of this
          Amendment.

     c.   No delay or omission by the Administrative Agent or any Lender in
          exercising or enforcing any of its rights and remedies shall operate
          as, or constitute, a waiver thereof. No waiver by the Administrative
          Agent or any Lender of any of its rights and remedies on any one
          occasion shall be deemed a waiver on any subsequent occasion, nor
          shall it be deemed a continuing waiver.

     d.   This Amendment incorporates all discussions and negotiations among the
          Borrower, the Guarantors, the Administrative Agent and the Lenders,
          either express or implied, concerning the matters included herein, any
          custom, usage, or course of dealings to the contrary notwithstanding.
          No such discussions, negotiations, custom, usage, or course of
          dealings shall limit, modify, or otherwise affect the provisions
          hereof. No modification, amendment, or waiver of any provision of this
          Amendment or of any provision of any other agreement between the
          Borrower, the Guarantors, the Administrative Agent or any Lender shall
          be effective unless executed in writing by the party to be charged
          with such modification, amendment and waiver.

                                       3
<PAGE>

     e.   Except as modified hereby, all terms and conditions of the Credit
          Agreement, the Limited Waiver, the Existing Waiver, and the other
          Credit Documents remain in full force and effect, and the Borrower and
          Guarantors hereby ratify and confirm all of the terms and conditions
          and warranties and representations set forth therein, and shall
          continue to comply therewith.

     f.   This Amendment shall be deemed to constitute a "Credit Document" for
          all purposes under the Credit Agreement.

     g.   The Borrower and each Guarantor shall execute such instruments and
          documents as the Administrative Agent and the Lenders may from time to
          time request in connection with the Credit Agreement and the other
          Credit Documents, this Agreement and the arrangements contemplated
          hereby.

                       [signature blocks on next pages]

                                       4
<PAGE>

     It is intended that this Amendment take effect as a sealed instrument.

                                       CYBEX INTERNATIONAL, INC.

                                       By  /S/ John Aglialoro
                                         ---------------------------------

                                       Print Name:  John Aglialoro
                                                  ------------------------

                                       Title:   CEO
                                             -----------------------------

                                       CYBEX FINANCIAL CORP.

                                       By  /S/ John Aglialoro
                                         ---------------------------------

                                       Print Name:  John Aglialoro
                                                  ------------------------

                                       Title:   CEO
                                             -----------------------------

                                       EAGLE PERFORMANCE SYSTEMS, INC.

                                       By  /S/ John Aglialoro
                                          --------------------------------

                                       Print Name:  John Aglialoro
                                                  ------------------------

                                       Title:  CEO
                                             -----------------------------

                                       GENERAL MEDICAL EQUIPMENT, LTD.

                                       By  /S/ John Aglialoro
                                         ---------------------------------

                                       Print Name:  John Aglialoro
                                                  ------------------------

                                       Title:  CEO
                                             -----------------------------

                                       LUMEX BED SYSTEMS, INC.

                                       By  /S/ John Aglialoro
                                         ---------------------------------

                                       Print Name:  John Aglialoro
                                                  ------------------------

                                       Title:  CEO
                                             -----------------------------

                                       5
<PAGE>

                                       CYBEX FITNESS GERATE VERTRIEBS, GMBH

                                       By  /S/ John Aglialoro
                                        ----------------------------------

                                       Print Name:  John Aglialoro
                                                  ------------------------

                                       Title:  CEO
                                             -----------------------------

                                       TECTRIX FITNESS EQUIPMENT, INC.

                                       By  /S/ John Aglialoro
                                         ---------------------------------

                                       Print Name:  John Aglialoro
                                                  ------------------------

                                       Title:  CEO
                                             -----------------------------

AGREED AND ACCEPTED BY

FIRST UNION NATIONAL BANK

By:  /S/ Ron R. Ferguson
   -------------------------------

Print Name: Ron R. Ferguson
           -----------------------

Title:  Senior Vice President
      ----------------------------

FLEET NATIONAL BANK

By:  /S/ Kevin M. Behan
   -------------------------------

Print Name: Kevin M. Behan
           -----------------------

Title:  Vice President
      ----------------------------

                                       6<PAGE>

                                                                    Exhibit 10.1

   Paradigm Genetics, Inc. has omitted from this Exhibit 10.1 portions of the
Agreement for which Paradigm Genetics, Inc. has requested confidential treatment
  from the Securities and Exchange Commission pursuant to Rule 24b-2 under the
   Securities Exchange Act of 1934. The portions of the Agreement for which
 confidential treatment has been requested have been filed separately with the
        Securities and Exchange Commission and are marked by asterisks.

                               AMENDMENT NUMBER 2

                                       To

               Monsanto/Paradigm Genetics Collaboration Agreement
<PAGE>

      THIS IS AN AMENDMENT to the Monsanto/Paradigm Genetics Collaboration
Agreement dated as of November 17, 1999 (the "Agreement"), effective as of
________, by and between Paradigm Genetics Inc., a corporation organized under
the laws of Delaware, having its principal place of business at 108 Alexander
Drive, Building 1A, P.O. Box 14528, Research Triangle Park, North Carolina 2709
("Paradigm") and Monsanto Company ("Monsanto"), a Delaware corporation, having a
principal place of business at 800 North Lindbergh Boulevard, St. Louis,
Missouri 63167.

      WHEREAS, the parties have agreed to modify the Agreement as set forth
herein.

      NOW, THEREFORE, in consideration of the mutual covenants and agreements
hereinafter set forth, the parties agree as follows:

                                 1. DEFINITIONS

1.1 Terms defined in the Agreement are used herein as so defined.

1.2 In addition, for purposes of the Agreement, as amended hereby, the following
words and phrases shall have the following meanings:

            1.34 Homolog

            "Homolog" shall mean DNA which encodes a protein whereby the protein
            is more than 50% similar to a protein encoded by Monsanto DNA
            Information, as determined using a global alignment across the
            entire length of the two proteins with the GCG GAP program
            configured with default parameters (matrix = Blossum62, Gap Creation
            Penalty = 8, Gap Extension Penalty = 2) and whereby the Homolog and
            the Monsanto DNA Information confers substantially the identical
            trait using standard transgene technologies, including but not
            limited to over-expression, antisense or knockout technologies. As
            an example of "substantially the identical trait," cold tolerance of
            2 degrees centigrade should be considered to be substantially the
            identical trait as cold tolerance of 10 degrees centigrade, but not
            considered the substantially identical trait as freeze tolerance

                                       2
<PAGE>

            (below 0 degrees centigrade) or heat tolerance (above 28 degrees
            centigrade).

            1.35 Monsanto Designated Crop

            "Monsanto Designated Crop" shall mean all cereal crops (including
            corn, wheat, rice and barley), all oil crops (including soybean,
            oilseed rape, canola and sunflower), sorghum, potato, cotton,
            alfalfa, sugarcane and turf.

            1.36 Monsanto Enabling Assets

            "Monsanto Enabling Assets" shall mean the technologies that are
            subject to the claims of the patents and patent applications and any
            and all patents maturing from applications that are divisionals,
            continuations or continuations-in-part of these applications and any
            and all reissues or extensions of any of the foregoing that are
            listed in Appendix L. Monsanto Enabling Assets are a subset of
            Monsanto Enabling Technology.

            1.37 Paradigm Fine Chemical Field

            "Paradigm Fine Chemical Field" shall mean the production in any
            plant of fragrances, flavors (including, without limitation, mint),
            Drugs and Dietary Supplements.

            1.39 Paradigm Enabled Products

            "Paradigm Enabled Products" shall mean products whose development,
            manufacture, use or sale, in the absence of the license granted by
            Article 2.12, would infringe at least one (1) claim of an unexpired
            U.S. or foreign patent owned or controlled by Monsanto covering the
            Monsanto Enabling Assets.

            1.40 Paradigm Technology

            "Paradigm Technology" shall mean any materials, know-how,
            information, discoveries or inventions that are discovered or
            developed by Paradigm or in-licensed by Paradigm.

                                       3
<PAGE>

            1.41 Transcription Factor

            "Transcription Factor" shall mean a protein that associates with or
            near the promoter region of a gene and thereby regulates
            transcription of such gene.

            1.42 Submitted for Regulatory Approval

            "Submitted for Regulatory Approval" shall mean a submission to the
            appropriate regulatory agency in any one of the United States, the
            European Union and Japan of a properly completed application that,
            if approved by the agency, would permit commercialization of the
            product without filing any additional applications. Whether or not
            the agency approves of the product or requires additional
            information is not relevant in determining the products' status as
            Submitted for Regulatory Approval.

            1.43 Permitted Assignee

            "Permitted Assignee" shall mean an entity that did not derive
            significant revenues from the sale of seeds or crop protection
            products in its most recent fiscal year preceding the date of
            determination of whether such entity is a Permitted Assignee.

            1.44 Nominations

            "Nominations" shall mean either 1) Arabidopsis sequence-verified
            constructs in the appropriate binary vectors; or 2) as Arabidopsis
            sequence information and suggested 5' and 3' primers for PCR-based
            cloning at Paradigm.

            1.45 Reservations

            "Reservations" shall mean Arabidopsis DNA sequence information which
            comprises either the full sequence of a gene (including the start
            and stop codon) or sufficient information to uniquely identify a
            single gene.

            1.46 Drugs and Dietary Supplements

            "Drugs" and "Dietary Supplements" shall have the meaning as set out
            in 21

                                       4
<PAGE>

            U.S.C. ss.ss. 321(g) and (ff) as of January 23, 2000.

      1.3 Amended Definitions

      The Agreement is amended by replacing Articles 1.11 and 1.18 with the
      following Article.

            1.11. Improvements

            "Improvements" shall mean any improvements to Monsanto Enabling
            Technology and Monsanto Enabling Assets. Improvements may or may not
            result in patentable subject matter.

            1.18 Net Product Revenues

            "Net Product Revenues" shall mean the gross invoiced sales of
            Licensed Products or Paradigm Enabled Products received by Paradigm,
            its Affiliates or, in the case of Paradigm Enabled Products, its
            licensee during the applicable period in arm's length transactions
            after deduction of the following items, provided and to the extent
            such items are actually incurred and do not exceed reasonable and
            customary amounts in each market in which such sales occurred: (1)
            trade and quantity discounts and rebates; (ii) credits or allowances
            made for rejection or return of previously sold Licensed Products or
            Paradigm Enabled Products; (iii) any tax or government charge levied
            on the sale, such as value added tax (but not including income tax);
            and (iv) any charges for freight or insurance. In the event that the
            Licensed Product or Paradigm Enabled Product is not sold or is used
            internally by Paradigm, an Affiliate of Paradigm, or, in the case of
            Paradigm Enabled Products, its licensee, or is sold or otherwise
            transferred to a third party for a price lower than if it had been
            sold to a third party in an arm's length transaction ("fair market
            value"), then Net Product Revenues shall be the fair market value of
            the Licensed Product or Paradigm Enabled Product.

                            2. CONVEYANCE OF RIGHTS

                                       5
<PAGE>

      2.1. Expanded Rights for Monsanto Enabling Assets

      The Agreement is amended by adding the following Articles:

      2.12 License to Paradigm: Additional Rights to Monsanto Enabling Assets in
      Paradigm Fine Chemical Field.

      In addition to the rights granted in Article 2.9, Monsanto grants to
      Paradigm under Monsanto's interest in Monsanto Enabling Assets, (a) a
      worldwide non-exclusive license to use Monsanto Enabling Assets in the
      Paradigm Fine Chemical Field, and (b) a worldwide non-exclusive license to
      develop, make, have made, import, use, sell, have sold and offer to sell:
      i) plants that have been developed with the use of Monsanto Enabling
      Assets that contain fragrances, flavors (including, without limitation,
      mint), Drugs and Dietary Supplements and; ii) fragrances, flavors
      (including, without limitation, mint), Drugs and Dietary Supplements
      produced from such plants, provided that such license shall not include
      the right to commercialize Drugs prior to September 1, 2002. Paradigm
      shall not have the right to grant sublicenses under the license granted by
      this Article 2.12 to third parties to use Monsanto Enabling Assets
      (including the right to transform plants with vectors supplied by
      Paradigm), but shall have the limited right to grant sublicenses under the
      license granted by this Article 2.12 to third parties (i) to propagate,
      grow, harvest, use, sell, have sold and offer to sell plants that both
      contain Paradigm Technology and have been developed or transformed by
      Paradigm with the use of Monsanto Enabling Assets including progeny of
      such plants, and (ii) to make, have made, import, use, sell, have sold and
      offer to sell fragrances, flavors (including, without limitation, mint),
      Drugs and Dietary Supplements produced from such plants that contain
      Paradigm Technology and progeny of such plants; further provided that if
      the Paradigm Technology has been in-licensed by Paradigm, then any such
      sublicense under this Article 2.12 shall not be exclusive to the provider
      of the in-licensed Paradigm Technology. The grant under this Article 2.12
      is limited to only those items of Monsanto Enabling Technology that are
      defined as Monsanto Enabling Assets. Paradigm shall be responsible for
      maintaining sufficient records on the use of Monsanto Enabling Assets so
      that plants can be identified. Paradigm agrees to grant and hereby grants
      a royalty-free, nonexclusive license to Monsanto to any Improvements
      created

                                       6
<PAGE>

      by Paradigm.

      2.2 Amended Grants

      The Agreement is amended by replacing Article 2.11 with the following
      Article.

            2.11. License to Paradigm: restriction on license

            Nothing in this Agreement shall be construed as granting a license
            under any Monsanto patents other than Licensed Patent Rights,
            Monsanto Enabling Technology and Monsanto Enabling Assets. No
            license is granted to any Licensed Product which infringes a
            Monsanto patent that is not included in Licensed Patent Rights,
            Monsanto Enabling Technology and Monsanto Enabling Assets.

                3. FUNDED PROJECT AND REPLACEMENT OF APPENDICES

      3.1 Revised Quantities of Monsanto DNA Information

      The Agreement is amended by replacing Articles 3.2.1 and 3.2.3 with the
      following Article:

            3.2.1 Monsanto DNA supplied

            In the case of Monsanto DNA Information relating to a species other
            than Arabidopsis, such Monsanto DNA Information shall be in the form
            of a DNA clone containing a full-length open reading frame or in a
            form that does not require any cloning on behalf of Paradigm. For
            each such non-Arabidopsis DNA, Paradigm will provide an appropriate
            ortholog from Arabidopsis, if one is available. Monsanto agrees to
            provide to Paradigm primers from Arabidopsis that Paradigm can use
            to obtain such orthologs. Under the Project Plan, Monsanto shall be
            limited to providing no more than [____]* non-Arabidopsis DNA of
            which no more than [____________]* will be from rice, no more than
            [____________]* will be from Aspergillus and no more than
            [____________]* will be from filamentous fungal phytopathogens.
            These amounts will be proportionally expanded if Monsanto exercises
            the options under Articles 4.1.5.2 or 4.1.5.3. Monsanto will use
            diligent efforts to assure that all Monsanto DNA Information is
            accurate.

            3.2.3 Counting for failed experiments

            In the event that Paradigm attempts diligently to insert the DNA
            from any Monsanto DNA Information into Arabidopsis as set forth in
            the Project Plan but is unable to do so, the remediation activities
            specified in the Project Plan will

                                       7
<PAGE>

            be undertaken and the achievement of the Production Target Levels
            will be calculated as specifically set forth in the Project Plan.

      3.2 Replacement Appendices B, C, F, and H

      Appendices B, C, F, and H are deleted from the Agreement and replaced with
      Appendices B, C, F, and H attached hereto. Appendix L and M are added to
      the Agreement.

      3.2.6 Nominations

      (a) Monsanto shall submit Nominations as set forth in the Project Plan.
      Paradigm shall provide Monsanto quarterly and within 5 business days of
      request with a list of Nominations for which Paradigm has not yet
      commenced the first attempt to clone a sense construct in accordance with
      the Project Plan. Monsanto shall have the right to withdraw any Nomination
      on such list and substitute a different Nomination from the list of
      Reservations by written notice given within five (5) business days of
      receipt of the list. Paradigm agrees to make further substitutions upon
      request to the extent that cloning for the requested substitute Nomination
      has not yet been attempted. The withdrawn Nomination shall revert to the
      status of a Reservation, subject to substitution pursuant to Section 3.2.4
      at Monsanto's option.

      (b) The parties shall, on a quarterly basis, review Paradigm's backlog of
      Nominations not yet successfully cloned and, if appropriate, shall reduce
      the rate at which Nominations are provided by Monsanto pursuant to the
      Project Plan to the level necessary to sustain target production levels
      and necessary work buffers at Paradigm.

                                  4. PAYMENTS

      4.1. The Agreement is amended by adding the following Articles.

            4.6 Royalties - Paradigm Enabled Products

            Paradigm shall pay a royalty based on the aggregate Net Product
            Revenues of all Paradigm Enabled Products sold by Paradigm or a
            licensee of Paradigm subject to the following conditions:

            4.6.1 Royalty Rate

            The royalty rate shall be based on the particular Monsanto Enabling
            Assets utilized in the development of the Paradigm Enabled Product
            as follows:

                                       8
<PAGE>

                  Monsanto Enabling Assets                     Royalty Rate
                  ------------------------                     ------------
                  35S Promoter                                         1.0%
                  NPT2 Antibiotic Resistance Gene                      0.5%
                  Agrobacterium Transformation                         1.0%

            4.6.2 Cumulative Royalties

            Royalties shall be paid on a product-by-product basis. In the event
            that only one Monsanto Enabling Asset is present or used in the
            product, for instance, 35S Promoter, then only one royalty shall be
            due and payable at the applicable rate regardless of the number of
            patents covering the particular Monsanto Enabling Asset practiced by
            Paradigm and sublicensees in connection with the production and
            commercialization of a particular Paradigm Enabled Product. In the
            event that two or more Monsanto Enabling Assets are present or used
            in the product, for instance, 35S Promoter and Agrobacterium
            Transformation, then the sum of the royalties shall be due (in the
            example, a 2% royalty would be due).

            4.6.2 No Non-Monetary Consideration for Sales:

            Paradigm shall not accept or solicit any non-monetary consideration
            in the sale by Paradigm or sublicensee of Paradigm of any Paradigm
            Enabled Product, other than as would be reflected in the calculation
            of Net Product Revenues, as the case may be.

                  5. CERTAIN USES OF MONSANTO DNA INFORMATION

      5.1. Effect of Uses of Monsanto DNA Information

      The Agreement is amended by adding the following Section 7.10.

            7.10 Effect of Uses of Monsanto DNA Information

            Without limiting the generality of the other provisions of this
            Article 7, if Paradigm utilizes Monsanto DNA Information or if
            Paradigm or Monsanto utilizes Project Technology developed in the
            course of carrying out the Project Plan for a third party or for
            itself and such use materially contributes to the

                                       9
<PAGE>

            conception or reduction to practice of any of the following:

                  (i) any Homolog of any gene represented by the Monsanto DNA
                  Information;

                  (ii) any gene whose transcription or translation is controlled
                  by Monsanto DNA Information or its Homolog;

                  (iii) any Arabidopsis Transcription Factor that regulates
                  transcription of Monsanto DNA Information or its Homolog; or

                  (iv) any protein which interacts with Monsanto DNA Information
                  or is in an interaction pathway with Monsanto DNA Information
                  and, in either case, that can be used to create the same trait
                  as such Monsanto DNA Information,

            then such invention or discovery shall be included in Project
            Technology and, if patented, Licensed Patents, with the exception
            that the inventions or discoveries from such use by Monsanto shall
            not be licensed to Paradigm and with the further exception that the
            licenses granted to Monsanto shall be limited to the field of
            Monsanto Designated Crops. The foregoing shall not apply to any
            other use of Monsanto DNA Information permitted by this Agreement,
            including without limitation use of Monsanto DNA Information and
            Project Technology to determine or confirm the function of DNA
            discovered without the use of Monsanto DNA Information described
            above. The foregoing shall not apply to any use of information
            obtained independently from the Project Plan by Paradigm, even if
            such information is the same as Monsanto DNA Information or Project
            Technology. In addition, Paradigm shall have the right to use
            Monsanto DNA Information in any way for the purpose of discovering
            genes or proteins that are targets for herbicides with the proviso
            that any gene or protein discovered shall be licensed to Monsanto as
            Licensed Patents for all uses other than as targets for herbicide
            discovery.

                                       10
<PAGE>

                                6. FUNDED PROJECT

      6.1. Amendments Relating To Supply Of Monsanto DNA Information

      The Agreement is amended by adding the following Articles 3.2.4, 3.2.5 and
      3.2.6.

            3.2.4 New Appendix M

            Within three months of signing this amendment and receiving all
            information necessary to calculate the formula set forth below,
            Monsanto shall deliver to Paradigm a new Appendix M which shall
            contain a list of Reservations. The number of Reservations on the
            list shall be determined by the following formula:

                                  N = 5000 - C
                                      --------
                                       (R X F)

            where:      N is the number of Reservations on the list;

                        C is the number of sense constructs that have been
                  created on the date the calculation is made

                        R is the success rate of Monsanto in converting
                  Reservations on the list into Nominations, which the parties
                  agree shall be [____]* for the term of this Agreement; and

                        F is equal to the success rate of Paradigm in converting
                        Nominations into sense constructs at the date the
                        calculation is made. F is a fraction in which the
                        numerator is the number of successful sense constructs
                        produced by Paradigm from Nominations according the
                        Project Plan over the two quarters preceding the
                        calculation and the denominator is the sum of the number
                        of successful sense constructs produced by Paradigm plus
                        the number of failures resulting from Paradigm's
                        attempts during the same two quarters preceding the
                        calculation. For purposes of this calculation, a failure
                        means that Paradigm has been unsuccessful in producing a
                        sense construct in four attempts as described in the
                        Project Plan.

                                       11
<PAGE>

            Unless as otherwise agreed by Paradigm or as provided by this
            Article, all future items of Monsanto DNA Information shall be
            selected from Reservations on Appendix M. If Monsanto proposes to
            remove a Reservation and substitute a different Reservation that is
            not on the list and represents an "available gene," such agreement
            by Paradigm will not be unreasonably withheld. For purposes of this
            Article, an "available gene" is one which, at the time of the
            proposed substitution, Paradigm has not previously analyzed for a
            third party and has not previously analyzed for itself, provided
            that Paradigm may only refuse a substitution on the basis that it
            has previously analyzed a gene for itself for one hundred (100) such
            genes during the term of the Agreement. Paradigm may not withhold
            agreement for any available gene unless such gene is one (a) for
            which Paradigm has created a plant transformation vector for a third
            party, or (b) for which Paradigm has a written research plan with a
            third party pursuant to which Paradigm intends to create a plant
            transformation vector (as demonstrated by written records) and in
            fact does so within six (6) months, or (c) which is the subject of
            an agreement with a third party, (d) which is the subject of an
            active negotiation with a third party as demonstrated by written
            records that becomes subject of an agreement within twelve months of
            the proposed date of substitution or (e) which is the subject of a
            published patent application of Paradigm for which Paradigm has
            developed functional information.

            Upon receipt of each quarterly data package from Paradigm pursuant
            to the Project Plan, and the necessary information for the
            calculation of "N" above, Monsanto will furnish to Paradigm a list
            of Reservations to be deleted from Appendix M so that the total
            remaining number is determined by the above formula. If Monsanto
            does not provide such list within 30 days of receipt of the
            necessary information, Paradigm shall notify Monsanto of such
            failure. If after an additional 15 days Monsanto has not provided
            such a list, Paradigm shall have the right to select Reservations to
            be deleted from the list and shall provide such selection to
            Monsanto.

            As an example of the operation of this process if the calculation is
            performed as of the end of [___]* and the total number of successful
            sense constructs produced

                                       12
<PAGE>

            in [_________]* was [____]* and the number of failures was [___]*
            during [_________]* and the total number of sense constructs created
            is [____]*

            F would be [____]*;

            C would be [____]*;

            and N would be [____]*.

            3.2.5 Monsanto DNA Information Previously Analyzed.

            Within ninety (90) days after submission of Appendix M, Paradigm
            agrees, to the extent it has the right to do so, to make the data
            from analysis it has already completed for any Reservation listed on
            Appendix M available to Monsanto, and if such data meets the
            requirements of a data package as described in the Project Plan,
            shall be counted in the throughput targets for the Project Plan in
            that quarter and if the data does not meet the requirements of a
            data package, then it shall be counted in the throughput targets for
            the Project Plan in the quarter that it is completed.

            3.2.6 Nominations

            (b)   Monsanto shall submit Nominations as set forth in the Project
                  Plan. Paradigm shall periodically provide Monsanto with a list
                  of Nominations for which Paradigm has not yet commenced the
                  first attempt to clone a sense construct in accordance with
                  the Project Plan and Monsanto shall have the right to withdraw
                  any Nomination on such list and substitute a different
                  Nomination from the list of Reservations by written notice
                  given within five (5) business days of receipt of the list.
                  The withdrawn Nomination shall revert to the status of a
                  Reservation, subject to substitution pursuant to Section 3.2.4
                  at Monsanto's option.

            (c)   The parties shall, on a quarterly basis, review Paradigm's
                  success rate in converting Nominations into sense constructs
                  and, if appropriate to reflect such success rate, shall modify
                  the rate at which Nominations are provided by Monsanto
                  pursuant to the Project Plan.

                                       13
<PAGE>

                               7. OTHER AMENDMENTS

      7.1.  The Agreement is amended by deleting Section 3.5.1 from the
            Agreement.

      7.2.  The Agreement is amended by deleting Section 4.1.1.1 from the
            Agreement.

      7.3.  The Agreement is amended by replacing Article 11.2 with the
            following:

            11.2 Assignability:

            The rights and obligations acquired herein by the parties are not
            assignable, transferable or otherwise conveyable, in whole or in
            part (by operation of law or otherwise) to any third party without
            the consent of the other party, which shall not be unreasonably
            withheld, except that either party may, without such consent, assign
            its rights and obligations to any purchaser of all or substantially
            all of the assets of the party related to this Agreement or to any
            successor corporation resulting from any merger or consolidation of
            a party (in either case, an "Acquirer"); provided, however, that if
            the party so assigning its rights and obligations is Paradigm and
            the Acquirer is not a Permitted Assignee, then (a) Paradigm may give
            written notice of the proposed transaction to Monsanto at least
            twenty (20) days prior to the expected closing thereof, (b) Monsanto
            shall advise Paradigm in writing as to whether it will or will not
            exercise its right to terminate the license granted by Section 2.12
            in accordance with clause(c) of this sentence within ten (10) days
            of receipt of such notice from Paradigm, and (c) if Paradigm has not
            given notice in accordance with clause (a) or Monsanto has given
            notice that it will exercise its right to terminate in accordance
            with clause (b), Monsanto shall have the right, exercisable within
            thirty (30) days after the closing or notice of the closing of such
            transaction, whichever occurs later, to terminate the license
            granted by Section 2.12 with respect to Monsanto Enabling Assets
            except for any plant product that has been commercialized or
            Submitted for Regulatory Approval at the time of the closing of such
            transaction. Any Acquirer of Paradigm for which Monsanto does not,
            either in whole or in part, terminate the license to Monsanto
            Enabling Assets must agree in writing to

                                       14
<PAGE>

            accept such license under the terms set out in this Agreement or
            such license is terminated.

      7.4   Except as expressly set forth herein, the Agreement shall remain in
            full force and effect and shall not be deemed modified hereby.

                                       15
<PAGE>

      IN WITNESS WHEREOF, the parties hereto have caused this Amendment Number 2
to be executed and delivered as of the date set forth above.

PARADIGM GENETICS, INC.                      MONSANTO COMPANY

By                                           By
  ----------------------------------           ---------------------------------

Date                                         Date
    --------------------------------             -------------------------------

                                       16
<PAGE>

                            Appendix B - Project Plan

                                Project Overview

Paradigm Genetics and Monsanto are entering into a strategic relationship to
leverage Monsanto's investment in genomics by accessing Paradigm's functional
genomics expertise and capacity. The objective of the relationship is to develop
a robust gene discovery platform, utilizing the strengths of both parties.
Monsanto will provide Paradigm with genes for analysis in Arabidopsis. These
genes will be tested as [____]* different constructs, reflecting a combination
of sense and antisense constructs (Table 1). Paradigm will use diligent effort
to provide a full data package that provides functional data to strengthen or
obtain intellectual property claims for each gene. Paradigm will provide
Monsanto with customized data packages concerning those genes including the data
from the experiments conducted in this project.

Elements of the Project Plan are subject to change based on mutual agreement
within the Project Committee, as set forth in the Agreement to which this
Project Plan is attached.

                                      Scope

The goal of this project is the functional analysis of [____]* constructs (Table
1), over a period of six years, to determine their function and to evaluate
their potential as transgenes for improvement of agronomic and/or quality
traits. Morphological, biochemical, and stress screens for transgenic plants
carrying sense and/or antisense constructs will be collected over the entire
plant development cycle. The outlined data collection package will be applied to
Arabidopsis control and transgenic plants completing a whole life cycle. For
transgenic plants exhibiting lethal phenotypes at early developmental stages,
data will be collected up to the point of plant death and such data will be
delivered as full data sets corresponding to the respective gene.

                                  Research Plan

                    Arabidopsis Transgenic Plant Generation:

Genes will be provided by Monsanto, either as sequence-verified constructs in
the appropriate binary vector or as sequence information and suggested 5' and 3'
primers for PCR-based cloning at Paradigm. All of the genes will be isolated and
cloned into at least one sense or ectopic expression system and subsequently
transformed into Arabidopsis. For all non-Arabidopsis genes, Monsanto will
supply sequence-verified sense constructs. The numbers of Plants Transformed,
Phenotypic Analyses, and Full Analyses under Appendix C assume investigation of
a pool of genes of the following composition:

Table 1.
--------------------------------------------------------------------------------

Gene Class         Sense Constructs                  Anti-sense Constructs
--------------------------------------------------------------------------------
Arabidopsis        [____]*                           [__________________________
                                                     ___________________________
                                                     _______________]*
--------------------------------------------------------------------------------

Non-Arabidopsis    [____]* minus the number of       0
                   anti-sense constructs in the
                   pipeline by 6/21/01
--------------------------------------------------------------------------------

There will be a maximum of [____]* Arabidopsis sense constructs except that the
Arabidopsis may be decreased

                                       17
<PAGE>

with a corresponding increase in non-Arabidopsis genes. This may represent
analysis of more than a total of [____]* Arabidopsis genes if there are
antisense constructs for which the corresponding sense construct cannot be
obtained.

Table 2 outlines what materials need to be exchanged to facilitate generation
and analysis of transgenes.

<TABLE>
<CAPTION>
Table 2.
-------------------------------------------------------------------------------------------------------------
                        Monsanto has        Monsanto delivers              Paradigm delivers
-------------------------------------------------------------------------------------------------------------
<S>                     <C>                 <C>                            <C>
Arabidopsis             Full length,        -    PCR Primers               - [_______________________________
                        partial or no       -    cDNA clones, if             ________________________________
                        cDNA clone               available                   ________________________________
                                            -    Annotated Sequence          ________________________________
                                                 Information                 ________________________________
                                            -    Genomic DNA sequence        ________________________________
                                            -    Expected PCR                ________________________________
                                                 product size                ________________________________
                                            -    Priority assignment         ________________________________
                                                                             ________________________________
                                                                             ___________________]*
-------------------------------------------------------------------------------------------------------------
Non-Arabidopsis         Full-length clone   -
                                            -    -Annotated Sequence       - [_______________________________
                                                 Information                 ________________________________
                                            -    Sequence-verified           ________________________________
                                                 sense construct in          ________________________________
                                                 binary vector as            ________________________________
                                                 purified DNA                _____________________]*
                                            -    Consensus sequence
                                                 for each construct
-------------------------------------------------------------------------------------------------------------
                                            -                              -
-------------------------------------------------------------------------------------------------------------
</TABLE>

Genes will be selected on a quarterly basis. To date, [____]* Arabidopsis genes,
including [___]* controls and [___]* non-Arabidopsis sense clones, have been
submitted. A delivery schedule to accommodate the conversion to a sense pipeline
was discussed at a meeting at Paradigm on June 18, 2001 and is shown below:

<TABLE>
<CAPTION>
Table 3
-------------------------------------------------------------------------------------------------------------

Process                                        Q7     Q8       Q9      Q10      Q11    Q12     Q13     Q14
-------------------------------------------------------------------------------------------------------------
<S>                                            <C>    <C>      <C>     <C>      <C>    <C>     <C>     <C>
Nominations Received/Quarter                   [_]*   [__]*    [_]*    [__]*    [_]*   [_]*    [_]*    [_]*
-------------------------------------------------------------------------------------------------------------

Constructs/Quarter from Monsanto               [_]*   [__]*    [_]*    [__]*    [_]*   [_]*    [_]*    [_]*
-------------------------------------------------------------------------------------------------------------
</TABLE>

* [ ]* of the [ ]* nominations for Q8 will be delivered to Paradigm by the end
of September 2001.

All Arabidopsis genes submitted from June 21, 2001 onward will be analyzed only
in the sense orientation. The intent of the plan shown above is to provide
enough nominations and clones to allow the potential of [___]* % achievement of
milestone production targets. This plan results in submission of Arabidopsis
genes and clones sufficient for the entire collaboration by the beginning of Q14
of the collaboration. For all non-Arabidopsis genes, Monsanto will provide DNA
sequence information as well as DNA constructs containing full-length open
reading frames of the respective genes suitable for expression in Arabidopsis
using vectors provided by Paradigm as described above unless otherwise
unanimously approved by the Project Committee.

All genes will be cloned using standard PCR protocols for amplification, based
on the information provided by

                                       18
<PAGE>

Monsanto. Paradigm will clone the Arabidopsis genes (sense and antisense) and
Monsanto will clone the non-Arabidopsis genes. Paradigm will attempt to clone
the full-length ORF (methionine to stop codon) via RT-PCR, PCR from cloned cDNA
or genomic PCR with the primer sequences supplied by Monsanto. A total of four
attempts will be made at Paradigm. The first attempt will be RT-PCR or PCR
amplification of cloned cDNA. All failures from this reaction will be subjected
to genomic PCR. Failure from this round will trigger a reordering of the cloning
primers from a different vendor; using the new primers, a second round of
attempts from both cDNA and genomic DNA will be conducted. In the case where no
construct is obtained after these four attempts, Monsanto will attempt to
perform PCR using alternative strategies and, if successful, will return the
sequence-verified clones in binary vectors to the Paradigm cloning pipeline. In
order for genes to enter Monsanto's remediation process, Paradigm will provide
CGPG numbers of declared failures via the tracking database, report the reason
for the failure, and send primers to the appropriate Monsanto cloning group. For
remediations that are returned to Monsanto by August 31, 2001, Monsanto will
have until December 31, 2001 to perform remediation and return the clones to
Paradigm. For remediations that are returned to Monsanto after August 312001,
Monsanto will have four months to perform the remediations and to return the
clones to Paradigm. If Monsanto cannot provide the clone, then Paradigm's
efforts will be counted as [___]* % of a data package for that quarter. Paradigm
must report the remediations and return the primers to Monsanto for the
remediations to ultimately count as [___]* % of a data package under the
situation where Monsanto cannot remediate.  If Monsanto provides the clone,
then Paradigm will be compensated for the data package upon completion of the
analysis as if the construct had never failed and entered remediation. The
clones abandoned by Monsanto will be reported to Paradigm quarterly. A credit of
data packages, computed as [___]* % of the number of constructs for which
Monsanto failed to obtain a clone, will be counted toward Paradigm's quarterly
deliverable quota. For each quarter, this number will be credited to all
components (i.e., Constructs, Plant Transformation, Plate Phenomics, Soil
Phenomics, Full Analysis) of the quarterly quota, as presented in "Appendix C:
Project Plan Production Target Levels," and to the total project quota of
[____]* data packages.

All constructs made at Paradigm or Monsanto will be verified by DNA sequencing.
For antisense constructs, this will comprise single pass 5' and 3' sequence
runs, which will be compared with the authentic deduced protein sequence
provided by Monsanto. All sense constructs will be fully sequenced to generate a
high-quality consensus sequence. Both the nucleotide and derived amino acid
sequence corresponding to this consensus will be compared to the sequence
provided by Monsanto.
[_______________________________________________________________________________
___________________________________]* Paradigm will post all sequences obtained
from both antisense and sense constructs on the secure website for independent
confirmation of successful construct generation by Monsanto.

[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________

                                       19
<PAGE>

________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
____________________________________________________________________________]*

                            Standard Plant Phenomics:

[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
____________________________________________________________________________]*

Table 3A. Growth Stage Defining Measurements
--------------------------------------------------------------------------------
Description                         Measurement
--------------------------------------------------------------------------------
[______________________]*           [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]*           [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]*           [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]*           [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]*           [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]*           [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]*           [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]*           [_______________________________________]*
--------------------------------------------------------------------------------
[______________________]*           [_______________________________________]*
--------------------------------------------------------------------------------

                                       20
<PAGE>

Table 3B. Detailed Measurements
--------------------------------------------
[____________________________]*
--------------------------------------------------------------------------------
[____________________________]*             [____________________________]*
--------------------------------------------------------------------------------
[____________________________]*             [____________________________]*
--------------------------------------------------------------------------------
[____________________________]*             [____________________________]*
--------------------------------------------------------------------------------
[____________________________]*             [____________________________]*
--------------------------------------------------------------------------------
[___________]*                              [____________________________]*
--------------------------------------------------------------------------------
[___________]*                              [____________________________]*
--------------------------------------------------------------------------------
[___________]*                              [____________________________]*
--------------------------------------------------------------------------------
[___________]*                              [____________________________]*
--------------------------------------------------------------------------------
[____________________________]*             [____________________________]*
--------------------------------------------------------------------------------
[___________]*                              [____________________________]*
--------------------------------------------------------------------------------
[______]*                                   [____________________________]*
--------------------------------------------------------------------------------
[_______________]*                          [____________________________]*
--------------------------------------------------------------------------------
[_______________]*                          [____________________________]*
--------------------------------------------------------------------------------
[_______________]*                          [____________________________]*
--------------------------------------------------------------------------------
[_______________]*                          [______________]*
--------------------------------------------------------------------------------
[_______________]*                          [______________]*
--------------------------------------------------------------------------------
[_______________]*                          [______________]*
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
____________________________________________________________________________]*

Table 4. Dynamically scheduled data collection activities.
--------------------------------------------------------------------------------
Measurement                Start Trigger Event  Stop Trigger Event   Plants to
                                                                     Analyze(1)
--------------------------------------------------------------------------------
[___________________]*     [_________]*         [_____________]*     [_____]*
--------------------------------------------------------------------------------
[___________________]*     [_________]*         [_____________]*     [_____]*
--------------------------------------------------------------------------------
[___________________]*     [_________]*         [_____________]*     [_____]*
--------------------------------------------------------------------------------
[___________________]*     [_________]*         [_____________]*     [_____]*
--------------------------------------------------------------------------------
[___________________]*     [_________]*         [_____________]*     [_____]*
--------------------------------------------------------------------------------
[___________________]*     [_________]*         [_____________]*     [_____]*
--------------------------------------------------------------------------------
[___________________]*     [_________]*         [_____________]*     [_____]*
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
[___________________]*     [_________]*         [_____________]*     [_____]*
--------------------------------------------------------------------------------

                                       21
<PAGE>

<TABLE>
<CAPTION>
Table 5. Growth-stage-specific data collection events.
---------------------------------------------------------------------------------------------------------------
Trigger        Measurement                                 Data
Stage(1)                                                   Type(2)    8.    9.     Notes    10.   Plants to
                                                                                   /File          Analyze(4)
                                                                                   Code(3)

---------------------------------------------------------------------------------------------------------------
<S>            <C>                                         <C>        <C>   <C>             <C>
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*  [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*  [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*  [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*  [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*  [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*  [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*                  [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*                  [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*  [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*  [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
</TABLE>

                                       22
<PAGE>

<TABLE>
<S>            <C>                                         <C>        <C>   <C>             <C>
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*                  [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*                  [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*                  [_______]*
---------------------------------------------------------------------------------------------------------------

---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*  [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*  [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*  [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*  [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*     [_]*                  [_______]*
---------------------------------------------------------------------------------------------------------------

---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*                           [_______]*
---------------------------------------------------------------------------------------------------------------
[_____]*       [_________________________]*                [___]*           [______]*       [_______]*
---------------------------------------------------------------------------------------------------------------
</TABLE>

[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*

                             Biochemical Profiling:

                                       23
<PAGE>

[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*

[___________________________]*
[___________________________]*
[___________________________]*
[___________________________]*
[___________________________]*

[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*

Sample Processing and Extraction

[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*

                              Metabolic Profiles

[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
_____________________________________________________________________________]*[
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*

Table 7.

                                       24
<PAGE>

------------------------------------------------------------------------------
Metabolite                      Pathway            Class
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------
[_______________]*              [______]*          [_______________]*
------------------------------------------------------------------------------

TABLE 8
----------------------------------------------------------------------
Metabolite                    Pathway           Class
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------

                                       25
<PAGE>

----------------------------------------------------------------------
[_____________________]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------

                                       26
<PAGE>

----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------

                                       27
<PAGE>

----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*          [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------

                                       28
<PAGE>

----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------
[_____________________]*      [______]*         [______]*
----------------------------------------------------------------------

                          Physiological stress screens:

[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________

                                       29
<PAGE>

________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*

The current list of screens along with a summary of the approved or proposed
(for PEG) SOP is listed in Table 9. .

<TABLE>
<CAPTION>
Table 9. Summary of Physiological Stress Screens
-------------------------------------------------------------------------------------------------------------
Screen              Growth Conditions     Plate/Soil                 Attributes               Quarter
                                                                                              Implemented
-------------------------------------------------------------------------------------------------------------
<S>                 <C>                   <C>                        <C>                      <C>
[______]*           [___________________  [_______________________   [_____________________   [___]*
                    ____________________  ________________________   ______________________
                    ____________________  ________________________   ______________________
                    _____________]*       ______]*                   ______]*
-------------------------------------------------------------------------------------------------------------
[______]*           [___________________  [_______________________   [_____________________   [___]*
                    ____________________  ________________________   ______________________
                    _____________]*       ______]*                   ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______]*
-------------------------------------------------------------------------------------------------------------
[______]*           [___________________  [_______________________   [_____________________   [___]*
                    ____________________  ________________________   ______________________
                    _____________]*       ______]*                   ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______]*
-------------------------------------------------------------------------------------------------------------
[______]*           [___________________  [_______________________   [_____________________   [___]*
                    ____________________  ________________________   ______________________
                    _____________]*       ______]*                   ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______]*
-------------------------------------------------------------------------------------------------------------
                    [___________________  [_______________________   [_____________________   [___]*
                    ____________________  ________________________   ______________________
                    _____________]*       ______]*                   ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______]*
-------------------------------------------------------------------------------------------------------------
[______]*           [___________________  [_______________________   [_____________________   [___]*
                    ____________________  ________________________   ______________________
                    _____________]*       ______]*                   ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______]*
-------------------------------------------------------------------------------------------------------------
</TABLE>

                                       30
<PAGE>

<TABLE>
<S>                 <C>                   <C>                        <C>                      <C>
-------------------------------------------------------------------------------------------------------------
                                                                     ______________________
                                                                     ______]*
-------------------------------------------------------------------------------------------------------------
[______]*           [___________________  [_______________________   [_____________________   [___]*
                    ____________________  ________________________   ______________________
                    _____________]*       ______]*                   ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______]*
-------------------------------------------------------------------------------------------------------------
[______]*           [___________________  [_______________________   [_____________________   [___]*
                    ____________________  ________________________   ______________________
                    _____________]*       ______]*                   ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______________________
                                                                     ______]*
-------------------------------------------------------------------------------------------------------------
</TABLE>

[_______________________________________________________________________________
______________________________________________________________________________]*

It is currently anticipated that additional screens will be developed from those
listed below and that the scope of work will be similar to the plate screens
described in the Table 9.

[______________]*
[______________]*
[______________]*
[______________]*
[______________]*

The Project Committee has the right to substitute one screen for another as long
as resources are equivalent. Specific protocols and changes to approved SOPs
will be discussed and approved by the Project Committee.

                            Data Format and Transfer:

Data will be collected and transferred to Monsanto in the form of computer
files.

[_______________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*

[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*

                                       31
<PAGE>

                                   Appendix C:
                     Project Plan Production Target Levels.

                      Production Target Levels per Quarter

                           Plant           Plate         Soil
        Constructs    Transformation     Phenomics     Phenomics   Full Analysis

Q1         [_]*
Q2         [_]*
Q3         [_]*            [_]*
Q4         [_]*            [_]*
Q5         [_]*            [_]*             [_]*         [_]*          [_]*
Q6         [_]*            [_]*             [_]*         [_]*          [_]*
Q7         [_]*            [_]*             [_]*         [_]*          [_]*
Q8         [_]*            [_]*             [_]*         [_]*          [_]*
Q9         [_]*            [_]*             [_]*         [_]*          [_]*
Q10        [_]*            [_]*             [_]*         [_]*          [_]*
Q11        [_]*            [_]*             [_]*         [_]*          [_]*
Q12        [_]*            [_]*             [_]*         [_]*          [_]*
Q13        [_]*            [_]*             [_]*         [_]*          [_]*
Q14        [_]*            [_]*             [_]*         [_]*          [_]*
Q15        [_]*            [_]*             [_]*         [_]*          [_]*
Q16        [_]*            [_]*             [_]*         [_]*          [_]*
Q17        [_]*            [_]*             [_]*         [_]*          [_]*
Q18        [_]*            [_]*             [_]*         [_]*          [_]*
Q19        [_]*            [_]*             [_]*         [_]*          [_]*
Q20        [_]*            [_]*             [_]*         [_]*          [_]*
Q21        [_]*            [_]*             [_]*         [_]*          [_]*
Q22                        [_]*             [_]*         [_]*          [_]*
Q23                                         [_]*         [_]*          [_]*
Q24                                         [_]*         [_]*          [_]*

TOTAL     [___]*           [ ]*            [___]*       [___]*        [___]*

  Full analysis consists of [________________________________________________]*.
Data delivery is only relevant for those stress screens implemented in a given
quarter.

                                       32
<PAGE>

                                   Appendix F
                                   Rice Option

<TABLE>
<CAPTION>
                                  --------------------------------------------------------------------
                                              Quarterly                     Production Target
                                               Payments                       Level Payments
                                  --------------------------------------------------------------------
<S>                                                      <C>                              <C>
Year 1
Up front access fees                                     [________]*
Q1                                                       [________]*                      [________]*
Q2                                                       [________]*                      [________]*
Q3                                                       [________]*                      [________]*
Q4                                                       [________]*                      [________]*
Year 2
Q5                                                       [________]*                      [________]*
Q6                                                       [________]*                      [________]*
Q7                                                       [________]*                      [________]*
Q8                                                       [________]*                      [________]*
Year 3
Q9                                                       [________]*                      [________]*
Q10                                                      [________]*                      [________]*
Q11                                                      [________]*                      [________]*
Q12                                                      [________]*                      [________]*
Year 4
Q13                                                      [________]*                      [________]*
Q14                                                      [________]*                      [________]*
Q15                                                      [________]*                      [________]*
Q16                                                      [________]*                      [________]*
Year 5
Q17                                                      [________]*                      [________]*
Q18                                                      [________]*                      [________]*
Q19                                                      [________]*                      [________]*
Q20                                                      [________]*                      [________]*

                                  --------------------------------------------------------------------
TOTAL                                                    [________]*                      [________]*
                                  ====================================================================
</TABLE>

                                       33
<PAGE>

                                   Appendix H
                         5 Year Increase in Arabidopsis
                                     Option

<TABLE>
<CAPTION>
                                   --------------------------------------------------------------------
                                               Quarterly                     Production Target
                                               Payments                       Level Payments
                                   --------------------------------------------------------------------
<S>                                                      <C>                              <C>
Year 1
Up-front access fees                                     [________]*
Q1                                                       [________]*                       [________]*
Q2                                                       [________]*                       [________]*
Q3                                                       [________]*                       [________]*
Q4                                                       [________]*                       [________]*
Year 2
Q5                                                       [________]*                       [________]*
Q6                                                       [________]*                       [________]*
Q7                                                       [________]*                       [________]*
Q8                                                       [________]*                       [________]*
Year 3
Q9                                                       [________]*                       [________]*
Q10                                                      [________]*                       [________]*
Q11                                                      [________]*                       [________]*
Q12                                                      [________]*                       [________]*
Year 4
Q13                                                      [________]*                       [________]*
Q14                                                      [________]*                       [________]*
Q15                                                      [________]*                       [________]*
Q16                                                      [________]*                       [________]*
Year 5
Q17                                                      [________]*                       [________]*
Q18                                                      [________]*                       [________]*
Q19                                                      [________]*                       [________]*
Q20                                                      [________]*                       [________]*

                                   --------------------------------------------------------------------
TOTAL                                                    [________]*                       [________]*
                                   ====================================================================
</TABLE>

                                       34
<PAGE>

                                   Appendix L

                            Monsanto Enabling Assets

[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
______________________________________________________________________________]*

[_______________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________

                                       35
<PAGE>

________________________________________________________________________________
______________________________________________________________________________]*

                                       36
<PAGE>

                                   APPENDIX M

                                Reservation List

                                       37

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]